A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
Michael R ShafiqueTerrence L FisherElizabeth E EvansJohn E LeonardDesa Rae E PastoreCrystal L MallowErnest SmithVikas MishraAndreas SchröderKevin M ChinJ Thaddeus BeckMegan A BaumgartRamaswamy GovindanNashat Y GabrailAlexander I SpiraNagashree SeetharamuYanyan LouAaron S MansfieldRachel E SanbornJonathan Wade GoldmanMaurice ZaudererPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
The combination of pepinemab with avelumab was well tolerated in NSCLC and showed signs of antitumor activity in immunotherapy-resistant and PD-L1-negative/low tumors.